当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost.

Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost.

Abstract：

:Many patients with metastatic breast cancer receive several types of chemotherapy, although it is recognized that there is a declining probability of response. A major problem confronts oncologists in deciding when to recommend to patients that no further chemotherapy should be given. To address this problem we have assessed prospectively, health-related quality of life (HRQL) and costs of health care for 35 patients with metastatic breast cancer receiving third line chemotherapy in a representative clinical situation. HRQL and utilities were measured longitudinally using the EORTC QLQ-C30 questionnaire and the time trade-off method. Patients received a median of 2 cycles of chemotherapy and lived a median of 4.3 months. Twelve patients (34%) had substantial (> 10 points) improvement in the Global QL subscale and more than 30% of patients had similar changes in emotional and social function. The median baseline utility score was 0.9 and utilities correlated poorly with HRQL subscale. Eighteen patients had measurable disease and one patients experienced a partial response. Grade 3/4 toxicity occurred in 30% of patients. The average cost of management from study entry to death was CDN$ 17,260 (approximately US$ 12,000). Sixteen percent of this cost was associated directly with chemotherapy while hospital admissions and outpatient visits accounted for 50% and 14% of the total cost respectively. We conclude that: (a) many patients receiving third line chemotherapy maintain or improve indices of HRQL despite short survival and a low response rate: this might be due to chemotherapy, placebo effect, or a shift in frame of reference for HRQL; (b) patients were unwilling to trade quantity for quality of life; and (c) response rates and survival may be overestimated in patients selected for clinical trials.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

McLachlan SA,Pintilie M,Tannock IF

doi

10.1023/a:1006123721205

subject

Has Abstract

pub_date

1999-04-01 00:00:00

pages

213-23

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

54

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.

    abstract：:In contrast to antigen-specific alphabeta-T cells (adaptive immune system), gammadelta-T cells can recognize and lyse malignantly transformed cells almost immediately upon encounter in a manner that does not require the recognition of tumor-specific antigens (innate immune system). Given the well-documented capacity o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0527-6

    authors： Beck BH,Kim HG,Kim H,Samuel S,Liu Z,Shrestha R,Haines H,Zinn K,Lopez RD

    更新日期：2010-07-01 00:00:00

  • Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue.

    abstract：:The purpose of the present study was to characterize primitive epithelial progenitor populations present in adult normal human mammary tissue using a combination of flow cytometry and in vitro colony assay procedures. Three types of human breast epithelial cell (HBEC) progenitors were identified: luminal-restricted, m...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1010615124301

    authors： Stingl J,Eaves CJ,Zandieh I,Emerman JT

    更新日期：2001-05-01 00:00:00

  • Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.

    abstract：PURPOSE:APOBEC3B belongs to the family of DNA-editing enzymes. A copy number variant targeting the genomic APOBEC3A-APOBEC3B locus has a significant impact on breast cancer risk, but the relative contribution of APOBEC3B is uncertain. In this study, we investigate a loss-of-function mutation that selectively targets AP...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-016-4100-9

    authors： Radmanesh H,Spethmann T,Enßen J,Schürmann P,Bhuju S,Geffers R,Antonenkova N,Khusnutdinova E,Sadr-Nabavi A,Shandiz FH,Park-Simon TW,Hillemanns P,Christiansen H,Bogdanova N,Dörk T

    更新日期：2017-02-01 00:00:00

  • Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.

    abstract：:Tamoxifen is currently the adjuvant treatment of choice for postmenopausal women with hormone-sensitive breast cancer. However, in the treatment of postmenopausal women with advanced disease, the third-generation aromatase inhibitor anastrozole ('Arimidex') has been shown to be at least as effective as tamoxifen, and ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1025455130476

    authors： Aapro MS,Forbes JF

    更新日期：2003-01-01 00:00:00

  • The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis.

    abstract：OBJECTIVE:Previous meta-analyses have examined the prognosis of women with pregnancy-associated breast cancer (PABC) as well as pregnancy that follows breast cancer diagnosis. Since then, many additional studies have been performed. We conducted an updated meta-analysis to examine the prognosis for women who become pre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-016-3989-3

    authors： Hartman EK,Eslick GD

    更新日期：2016-11-01 00:00:00

  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

    abstract：:FOXP3-expressing T regulatory lymphocytes (Tregs) have been described as putative mediators of immune tolerance, and thus facilitators of tumor growth. When found in association with various malignancies, Tregs are generally markers of poor clinical outcome. However, it is unknown whether they are also associated with...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2556-4

    authors： Lal A,Chan L,Devries S,Chin K,Scott GK,Benz CC,Chen YY,Waldman FM,Hwang ES

    更新日期：2013-06-01 00:00:00

  • Diet and risk for breast cancer recurrence and survival.

    abstract：:Dietary factors may influence the risk for breast cancer and also the prognosis following diagnosis and treatment. The aim of this study was to assess whether self-reported prediagnosis diet or other patient factors associated with breast cancer incidence were predictive of recurrence and survival. Patients (n = 149) ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006190820231

    authors： Saxe GA,Rock CL,Wicha MS,Schottenfeld D

    更新日期：1999-02-01 00:00:00

  • Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

    abstract：:The enumeration of circulating tumor cells (CTCs) provides important prognostic values in patients with metastatic breast cancer. Recent studies indicate that individual CTCs form clusters and these CTC-clusters play an important role in tumor metastasis. We aimed to assess whether quantification of CTC-clusters provi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3636-4

    authors： Mu Z,Wang C,Ye Z,Austin L,Civan J,Hyslop T,Palazzo JP,Jaslow R,Li B,Myers RE,Jiang J,Xing J,Yang H,Cristofanilli M

    更新日期：2015-12-01 00:00:00

  • Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma.

    abstract：:In a series of 205 node-negative breast cancers (NNBC), we determined staining by the novel antibody Ki-S1, a marker of tumor cell proliferation, in order to test its association with other prognostic variables and its prognostic significance. Ki-S1 was determined in routinely formalin-fixed paraffin-embedded tumor sa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806494

    authors： Bevilacqua P,Verderio P,Barbareschi M,Bonoldi E,Boracchi P,Dalla Palma P,Gasparini G

    更新日期：1996-01-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract：PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-020-05648-9

    authors： Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期：2020-07-01 00:00:00

  • Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.

    abstract：:The regulation of gene expression by steroid hormones plays an important role in the normal development and function of many organs, as well in the pathogenesis of endocrine-related cancers. Previous experiments have shown that many kallikrein genes are under steroid hormone regulation in breast cancer cell lines. We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9312-y

    authors： Paliouras M,Diamandis EP

    更新日期：2007-03-01 00:00:00

  • Interactions between the estrogen receptor, its cofactors and microRNAs in breast cancer.

    abstract：:The activity of selective estrogen receptor modulators (SERMs) is not fully explained by an estrogen receptor (ER) switch model that simply turns estrogen activity on or off. A better understanding of the mechanisms involved in estrogen signaling and the development of drug resistance could help stratify patients into...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-009-0429-7

    authors： McCafferty MP,McNeill RE,Miller N,Kerin MJ

    更新日期：2009-08-01 00:00:00

  • Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.

    abstract：:The effect of 17-beta-estradiol (E2) on the induction of osteolytic lesions by estrogen receptor (ER)-negative breast cancer cells was investigated in 4-week-old female nude mice. Exposure to exogenous E2 was found to increase osteolytic areas on radiographs up to 5.3 times in mice inoculated intracardially with MDA-2...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1022943127689

    authors： Winding B,Misander H,Høegh-Andersen P,Brünner N,Foged NT

    更新日期：2003-03-01 00:00:00

  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

    abstract：BACKGROUND:The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4115-x

    authors： Rosenberger LH,Weber R,Sjoberg D,Vickers AJ,Mangino DA,Morrow M,Pilewskie ML

    更新日期：2017-04-01 00:00:00

  • Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.

    abstract：:The transcriptome of breast cancers have been extensively screened with microarrays and large sets of genes associated with clinical features have been established. The aim of this study was to validate original gene sets on a large cohort of raw breast cancer microarray data with known clinical follow-up. We recovere...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-008-0242-8

    authors： Györffy B,Schäfer R

    更新日期：2009-12-01 00:00:00

  • Prognostic factors for patients with breast cancers 1cm and smaller.

    abstract：:The widespread use of mammography has resulted in the detection of an increasing number of small invasive breast cancers, i.e. those that are 1cm and smaller. Patients with these small cancers generally have a low incidence of axillary lymph node metastases, and this has led some to question the routine use of axillar...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1006130911110

    authors： Chen YY,Schnitt SJ

    更新日期：1998-01-01 00:00:00

  • Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.

    abstract：PURPOSE:The results of studies comparing survival in familial and sporadic breast cancer (BC) are inconsistent. A higher incidence of contralateral breast cancer (CBC) has been reported in familial BC. Ascertainment bias may influence both the reported familial CBC and survival. DESIGN:We assessed CBC incidence, dista...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9054-2

    authors： Tilanus-Linthorst MM,Bartels KC,Alves C,Bakri B,Crepin E,van den Ouweland A,Klijn JG,Meijers-Heijboer H,Brekelmans CT

    更新日期：2006-01-01 00:00:00

  • Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer.

    abstract：:The androgen receptor (AR) is a transcription factor mediating the action of androgens. The AR gene is localized on chromosome X and it contains a series of CAG trinucleotide repeats. The length of the CAG repeats varies among individuals and this polymorphism is believed to be related to AR transcriptional activity. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006356502820

    authors： Yu H,Bharaj B,Vassilikos EJ,Giai M,Diamandis EP

    更新日期：2000-01-01 00:00:00

  • A two-stage approach to genetic risk assessment in primary care.

    abstract：:Genetic risk prediction models such as BRCAPRO are used routinely in genetic counseling for identification of potential BRCA1 and BRCA2 mutation carriers. They require extensive information on the counselee and her family history, and thus are not practical for primary care. To address this gap, we develop and test a ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3686-2

    authors： Biswas S,Atienza P,Chipman J,Blackford AL,Arun B,Hughes K,Parmigiani G

    更新日期：2016-01-01 00:00:00

  • Polyamines metabolism and breast cancer: state of the art and perspectives.

    abstract：:Breast cancer (BC) is a common disease that generally occurs in women over the age of 50, and the risk is especially high for women over 60 years of age. One of the major BC therapeutic problems is that tumors initially responsive to chemotherapeutic approaches can progress to more aggressive forms poorly responsive t...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-014-3156-7

    authors： Cervelli M,Pietropaoli S,Signore F,Amendola R,Mariottini P

    更新日期：2014-11-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract：:Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1005872617944

    authors： Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期：1997-09-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract：PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4749-3

    authors： Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期：2018-07-01 00:00:00

  • Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.

    abstract：:The structure/activity relationships for inhibition of aromatase and cholesterol side-chain cleavage enzyme (CSCC) by aminoglutethimide and some of its analogues are reviewed. Although more effective against aromatase than CSCC, aminoglutethimide markedly inhibits both enzymes. Optimal competitive antagonism of aromat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：

    authors： Nicholls PJ,Daly MJ,Smith HJ

    更新日期：1986-01-01 00:00:00

  • Effect of two-4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer.

    abstract：:A number of endocrine treatments for advanced breast cancer seem to affect serum insulin-like growth factor I (IGF-I). The aim of our study was to investigate IGF-I levels in 33 postmenopausal patients with metastatic disease receiving the selective aromatase inhibitor 4-hydroxyandrostenedione: 250 mg (16 patients) or...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF00666055

    authors： Ferrari L,Zilembo N,Bajetta E,Buzzoni R,Noberasco C,Martinetti A,Celio L,Galante E,Orefice S,Cerrotta AM

    更新日期：1994-01-01 00:00:00

  • The nude mouse as an in vivo model for human breast cancer invasion and metastasis.

    abstract：:Human breast cancer xenografts only rarely invade and metastasize in nude mice, and have therefore only had limited use as a model for studying mechanisms involved in breast cancer spreading. However, recent reports describe differences not only between various cell lines but also between strains of immune-deficient m...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01833265

    authors： Brünner N,Boysen B,Rømer J,Spang-Thomsen M

    更新日期：1993-01-01 00:00:00

  • Dietary intake of isoflavones and breast cancer risk by estrogen and progesterone receptor status.

    abstract：:Epidemiological and experimental studies suggest that isoflavones may protect against breast cancer by acting as estrogen agonists or antagonists. A case-control study was conducted in southeast China in 2004-2005 to examine the association between dietary isoflavone intake and breast cancer risk by estrogen receptor ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0354-9

    authors： Zhang M,Yang H,Holman CD

    更新日期：2009-12-01 00:00:00

  • Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies.

    abstract：:Evidence for an association between fruit and vegetable intake and breast cancer risk is inconclusive. To clarify the association, we conducted a systematic review and meta-analysis of the evidence from prospective studies. We searched PubMed for prospective studies of fruit and vegetable intake and breast cancer risk...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-012-2118-1

    authors： Aune D,Chan DS,Vieira AR,Rosenblatt DA,Vieira R,Greenwood DC,Norat T

    更新日期：2012-07-01 00:00:00

  • Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

    abstract：:Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

    journal_title：Breast cancer research and treatment

    pub_type： 已发布勘误

    doi：10.1007/s10549-016-3752-9

    authors： Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

    更新日期：2016-04-01 00:00:00

  • Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients.

    abstract：BACKGROUND:The aim was to prove the low identification rate of sentinel lymph node biopsy (SNB) and to determine the feasibility of replacing axillary lymph node dissection (AND) in axillary lymph node positive patients after chemotherapy. METHODS:From October 2001 to July 2005, 875 consecutive patients with primary o...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-006-9330-9

    authors： Lee S,Kim EY,Kang SH,Kim SW,Kim SK,Kang KW,Kwon Y,Shin KH,Kang HS,Ro J,Lee ES

    更新日期：2007-05-01 00:00:00

  • Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.

    abstract：PURPOSE:Psychological resilience is an important ability for women with breast cancer to cope effectively with depression and anxiety. However, the demands of long-term hospital-based psychological rehabilitation interventions are not met in mainland China, where shorter hospital stays and longer home rehabilitation ar...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05368-9

    authors： Zhou K,Li J,Li X

    更新日期：2019-11-01 00:00:00